{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:34:51Z","timestamp":1792737291387,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jad.2023.11.023","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T15:11:48Z","timestamp":1699456308000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"346","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-5637","authenticated-orcid":false,"given":"Itsuki","family":"Terao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0497-944X","authenticated-orcid":false,"given":"Takahiro","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-0342","authenticated-orcid":false,"given":"Kaori","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6018-7506","authenticated-orcid":false,"given":"Wakako","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.11.023_bb0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.023_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.023_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00004714-199608000-00006","article-title":"A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation","volume":"16","author":"Baumann","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2023.11.023_bb2000","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1109\/TBME.2018.2877651","article-title":"Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG","volume":"66","author":"Cao","year":"2019","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.jad.2023.11.023_bb0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/NDT.S391096","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2023.11.023_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000332050","article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study)","volume":"81","author":"Fava","year":"2012","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2023.11.023_bb0045","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0050","first-page":"134","article-title":"Defining treatment-resistant depression. Depress","volume":"37","author":"Gaynes","year":"2020","journal-title":"Anxiety"},{"key":"10.1016\/j.jad.2023.11.023_bb0055","author":"Higgins"},{"key":"10.1016\/j.jad.2023.11.023_bb0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","article-title":"Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial","volume":"243","author":"Ionescu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.023_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archpsyc.1993.01820170065008","article-title":"A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression","volume":"50","author":"Joffe","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0070","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jad.2013.07.035","article-title":"Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)","volume":"151","author":"Kamijima","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.023_bb0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/pcn.12663","article-title":"Randomized, double-blind comparison of aripiprazole\/sertraline combination and placebo\/sertraline combination in patients with major depressive disorder","volume":"72","author":"Kamijima","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.11.023_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1192\/bjp.166.1.80","article-title":"Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine","volume":"166","author":"Katona","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0085","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hbm.23085","article-title":"The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study","volume":"37","author":"Li","year":"2016","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jad.2023.11.023_bb0090","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.023_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.11.023_bb0105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.11.023_bb0110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00004714-200302000-00013","article-title":"Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants","volume":"23","author":"Nierenberg","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.jad.2023.11.023_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis","volume":"302","author":"Nunez","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.023_bb0125","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb2010","unstructured":"R Core Team, 2022. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.jad.2023.11.023_bb0130","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","article-title":"Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis","volume":"79","author":"Rhee","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb2005","unstructured":"R\u00fccker G, K.U., K\u00f6nig, J., Efthimiou, O., Davies, A., Papakonstantinou, T., Schwarzer, G., 2022. netmeta: Network Meta-Analysis using Frequentist Methods_. R package version 2.5-0,. https:\/\/CRAN.R-project.org\/package=netmeta."},{"key":"10.1016\/j.jad.2023.11.023_bb0135","first-page":"627","article-title":"STAR*D: revising conventional wisdom","volume":"23","author":"Rush","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2023.11.023_bb0140","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.euroneuro.2012.02.006","article-title":"European Group for the Study of Resistant Depression (GSRD)\u2014where have we gone so far: review of clinical and genetic findings","volume":"22","author":"Schosser","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0145","article-title":"Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression","volume":"2698811221104058","author":"Scott","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0155","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0160","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0165","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2023.11.023_bb0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.2018.233","article-title":"Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis","volume":"214","author":"Strawbridge","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0175","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2023.11.023_bb0180","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"Suppl. 13","key":"10.1016\/j.jad.2023.11.023_bb0185","first-page":"23","article-title":"When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.22365\/jpsych.2021.046","article-title":"The burden and the challenge of treatment-resistant depression","volume":"32","author":"Touloumis","year":"2021","journal-title":"Psychiatriki"},{"key":"10.1016\/j.jad.2023.11.023_bb0195","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium","volume":"35","author":"Vazquez","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0004867419883341","article-title":"Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials","volume":"54","author":"Witt","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.023_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2045125313514767","article-title":"Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder","volume":"4","author":"Yoshimura","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0210","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/02698811231191912","article-title":"Ketamine: a new chapter for clinical psychopharmacology?","volume":"37","author":"Young","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.11.023_bb0215","first-page":"1668","article-title":"Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG Identifying ketamine responses in treatment-resistant depression using a wearable forehead EEG","volume":"66","author":"Zehong","year":"2019","journal-title":"I.E.E.E. Trans. Biomed. Eng."},{"key":"10.1016\/j.jad.2023.11.023_bb0220","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00004714-198804000-00007","article-title":"Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study","volume":"8","author":"Zusky","year":"1988","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723013836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723013836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:08:43Z","timestamp":1759032523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723013836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":47,"alternative-id":["S0165032723013836"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.11.023","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}